Basimglurant
Basimglurant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target metabotropic glutamate receptor 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 1 | 2 | — | — | — | 3 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 2 | — | — | — | 3 |
| Fragile x syndrome | D005600 | — | Q99.2 | — | 3 | — | — | — | 3 |
| Syndrome | D013577 | — | — | — | 3 | — | — | — | 3 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | — | — | 2 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Basimglurant |
| INN | basimglurant |
| Description | Basimglurant (INN) (developmental code names RG-7090, RO-4917523) is a negative allosteric modulator of the mGlu5 receptor which is under development by Roche and Chugai Pharmaceutical for the treatment of treatment-resistant depression (as an adjunct) and fragile X syndrome. As of November 2016, it has undergone phase II clinical trials for both of these indications.
|
| Classification | Small molecule |
| Drug class | metabotropic glutamate receptor antagonists, negative allosteric modulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 1034442-21-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301626 |
| ChEBI ID | — |
| PubChem CID | 11438771 |
| DrugBank | — |
| UNII ID | 3110E3AO8S (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
GRM5
GRM5
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 245 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use